This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
C3.ai's Q1 Top Line Takes a Hit: Can Growth Reaccelerate in FY26?
by Mrithunjoy Kaushik
AI's Q1 revenues drop 19% YoY due to weaker demo licenses. However, new deployments and partner-led deals support a path to stabilization.
Is Advantest (ATEYY) Outperforming Other Computer and Technology Stocks This Year?
by Zacks Equity Research
Here is how Advantest Corp. (ATEYY) and Leidos (LDOS) have performed compared to their sector so far this year.
Is It Worth Investing in Leidos (LDOS) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Leidos (LDOS) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Leidos (LDOS) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
Leidos (LDOS) reached $185.26 at the closing of the latest trading day, reflecting a +2.71% change compared to its last close.
Huntington Ingalls Marks Completion of 750th REMUS UUV for German Navy
by Zacks Equity Research
HII hits a milestone with its 750th REMUS UUV, as the German Navy deploys the advanced REMUS 300 for undersea missions.
Why Leidos (LDOS) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks.com featured highlights include Halozyme Therapeutics, Leidos and TransUnion
by Zacks Equity Research
Halozyme, Leidos and TransUnion earn upgraded broker ratings, with earnings growth and positive revisions boosting appeal.
Zacks.com featured highlights include Halozyme Therapeutics, Phibro, Leidos and PDD Holdings
by Zacks Equity Research
Halozyme, Phibro, Leidos and PDD Holdings shine as GARP picks, blending discounted valuations with strong long-term growth potential.
Bet on These 3 Stocks With Upgraded Broker Ratings for Robust Returns
by Swayta Shah
Broker upgrades boost Halozyme, Leidos and TransUnion, each projected for solid 2025 earnings growth and stronger returns.
4 PEG-Rated GARP Stocks That Offer Both Value and Growth
by Urmimala Biswas
Halozyme, Phibro, Leidos and PDD Holdings stand out as PEG-rated GARP picks, blending value and growth with solid long-term potential.
LDOS vs. NOW: Which Stock Is the Better Value Option?
by Zacks Equity Research
LDOS vs. NOW: Which Stock Is the Better Value Option?
Is Leidos (LDOS) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Leidos (LDOS). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Leidos (LDOS) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Leidos (LDOS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Reasons to Hold Roper Technologies in Your Portfolio Now
by Zacks Equity Research
ROP is riding software strength and strategic acquisitions, but high costs and debt temper the outlook.
Reasons to Include Leidos Stock in Your Portfolio Right Now
by Zacks Equity Research
LDOS' soaring EPS outlook, strong ROE, rising backlog and shareholder returns position it as a compelling buy.
Here's Why Leidos (LDOS) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Leidos (LDOS) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BigBear.ai Partners With Narval for Cargo Security in Panama
by Zacks Equity Research
BBAI teams with Narval to launch AI-powered cargo security in Panama, setting new standards for global supply-chain protection.
QUBT Q2 Earnings Match Estimates, Revenues Miss, Stock Down
by Zacks Equity Research
Quantum Computing posts a wider loss, and revenues lag estimates. However, milestones in quantum tech, NASA contract and index inclusion mark growth steps.
LDOS or NOW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LDOS vs. NOW: Which Stock Is the Better Value Option?
Is Leidos (LDOS) Stock Outpacing Its Computer and Technology Peers This Year?
by Zacks Equity Research
Here is how Leidos (LDOS) and Crexendo (CXDO) have performed compared to their sector so far this year.
Brokers Suggest Investing in Leidos (LDOS): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for Leidos (LDOS) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
C3.ai Posts Q1 Preliminary Results, Revamps Sales Team, Stock Down
by Zacks Equity Research
AI's first-quarter revenue miss and wider loss spark a 27% stock drop. The company revamps its sales team with industry veterans.
Embraer's Q2 Earnings Miss Estimates, Revenues Increase Y/Y
by Zacks Equity Research
Embraer posts wider-than-expected Q2 loss despite 21.8% revenue jump, with gains across all business segments and a record $29.7B backlog.